Posted by Michael Wonder on 11 Mar 2019
SMC - March 2019 decisions
11 March 2019 - The Scottish Medicines Consortium has today published advice accepting two new medicines.
Liposomal daunorubicin/cytarabine (Vyxeos) was accepted for the treatment of adults with a high-risk type of acute myeloid leukaemia.
Letermovir (Prevymis) was accepted following consideration through the SMC’s Patient and Clinician Engagement process for medicines for end of life and very rare conditions.
The committee was unable to accept tisagenlecleucel (Kymriah) for adult patients with diffuse B cell lymphoma who have relapsed or not responded after two previous lines of treatment.
